News & Perspective

Nov 27, 2007

Nov 27, 2007

FDA panel seeks stronger label warnings for 2 flu drugs

(CIDRAP News) – The US Food and Drug Administration's (FDA's) Pediatric Advisory Committee voted today to recommend stronger label warnings for two antiviral influenza medications—oseltamivir and zanamivir—that have been linked to reports of neuropsychiatric problems in children and teens, mainly in Japan.

Oseltamivir already carries a warning, but zanamivir currently carries no warning about reported neuropsychiatric effects.